Pfizer Inc. (PFE) Stock Analysis
Verdict: HOLD
Non-COVID portfolio momentum and high 5.38% yield support recovery, but looming 2026-2028 patent cliffs and debt keep valuation capped.
Investment score: 61/100
Analysis as of
Is Pfizer Inc. stock worth reviewing? The TradeMates thesis
The TradeMates model sees Pfizer Inc. (PFE) as a HOLD at $30.64, balancing operational execution in its non-COVID base and a 5.38% dividend yield against patent cliff headwinds and elevated leverage.
7-factor investment score
- Valuation: 58/100 (weight 20%)
- Financial Health: 50/100 (weight 15%)
- Technical Momentum: 70/100 (weight 15%)
- Earnings Quality: 80/100 (weight 15%)
- Insider Sentiment: 80/100 (weight 10%)
- Analyst Consensus: 40/100 (weight 10%)
- Risk-Adjusted Return: 50/100 (weight 15%)
Pfizer Inc. opportunities and risks
What speaks for PFE
- Non-COVID Base Portfolio Acceleration
What speaks against PFE
- Impending Patent Cliff (Loss of Exclusivity)
Peers and competitors
| Ticker | P/E | P/S | EV/EBITDA | Gross margin | Net margin | FCF yield |
|---|---|---|---|---|---|---|
| PFE | 43.4x | 2.7x | 21.2x | 77.9% | 6.4% | 6.7% |
| LLY | 45.7x | 15.4x | 30.7x | 83.6% | 31.9% | 1.5% |
| JNJ | 41.0x | 6.6x | 22.0x | 68.8% | 16.2% | 3.2% |
| MRK | 151.4x | 5.4x | 31.7x | 77.0% | 3.6% | 4.4% |
| BMY | 13.9x | 2.6x | 10.8x | 69.2% | 18.5% | 7.2% |
| RPRX | 27.6x | 11.7x | 22.0x | 89.4% | 32.1% | 10.0% |
| Peer median | 41.0x | 6.6x | 22.0x | 77.0% | 18.5% | 4.4% |
Frequently asked questions about Pfizer Inc. (PFE)
Is PFE stock a good investment?
The TradeMates model rates Pfizer Inc. as HOLD with an investment score of 61/100. The TradeMates model sees Pfizer Inc. (PFE) as a HOLD at $30.64, balancing operational execution in its non-COVID base and a 5.38% dividend yield against patent cliff headwinds and elevated leverage. This is algorithmic model output, not personal investment advice.
Is PFE stock a buy?
The TradeMates model verdict for PFE is HOLD with an investment score of 61/100. Treat this as a model signal to review, not a personal buy recommendation.